Elanco Just Had Its Best Quarter Since 2018 — And Nobody's Talking About It
While everyone's distracted by oil wars and Fed drama, a veterinary pharma comeback story is quietly going on a run
Ticker Ratings
While the financial world stress-eats over $101 Brent crude and Fed dissent drama, $ELAN is out here quietly having its moment. Elanco Animal Health just reported its best quarter since spinning out of Eli Lilly in 2018 — 10% growth on the farm side, high single-digit growth in pet health, and — plot twist — it's actually taking market share from $ZTS (Zoetis) and Merck's animal health unit. First time that's happened in years.
The omni-channel strategy is the sleeper detail here: Elanco is selling everything from dollar stores to specialty vet clinics, which is either genius diversification or the most chaotic distribution strategy in pharma. Either way, it's working. The company also boosted its full-year forecast, which in this macro environment — stagflation, gas at $4.50/gallon, consumer confidence at all-time lows per the University of Michigan — is basically a mic drop.
Retail sentiment hasn't caught up yet, which historically means one thing: the easy money is still on the table, just waiting for the crowd to show up.